I-Corps: Tailored Amorphous Multi-Porous (TAMP) Bioactive Scaffolds for Tissue Regeneration

组织工程学是通过刺激身体再生有缺陷的部分，为功能失调的组织或器官提供一种优越的治疗方法。这种用于硬组织(骨和牙齿)的首选治疗方法需要生物支架，理想情况下，生物支架必须具有：(A)生物相容性；(B)符合组织生长的生物降解性；(C)高度连通的大孔(100微米？S)，以促进细胞的内长、血管形成和养分输送；(D)叠加纳米孔，以引导细胞附着、迁移和分化；以及(E)具有催化再生过程的生物活性。市场上没有一种合成产品满足所有这些要求，包括生物活性玻璃(BG)--唯一一种用于硬组织再生的人造骨刺激材料。这个i-Corps团队已经开发出了制造一种新型生物活性材料的技术。与目前市场上基于生物活性玻璃的竞争产品相比，建议的技术提供了出色的骨诱导能力和卓越的降解性。它使人们能够根据特定的患者类型和缺陷的性质量身定做支架的降解行为，而不会影响组织生长。I-Corps团队通过使用新的制造方法将相互连接的纳米孔叠加在大孔上，解决了上述挑战：大孔为组织生长提供基本基质，纳米孔增强细胞响应，以及定制支架的能力-S降解率。其结果是产生了一种新的制造技术组合，用于生产符合特定患者类型需求的“定制非晶态多孔(TAMP)”支架。体外和体内试验已经证明了改进牙科和骨科患者治疗的原则和潜力。该捣固制造技术可容易地应用于具有诸如抗菌和防龋性等附加功能的新的BG组合物。当延伸到纤维形式时，这些夯实结构在机械上是柔性的。因此，夯实材料技术已经做好了商业化的准备。

Tissue engineering is providing a superior treatment for dysfunctional tissues or organs by stimulating the body to regenerate anew the defective part. This preferred treatment, yet to be established for hard tissue (bone and teeth), requires a bioscaffold, which must ideally have: (a) biocompatibility; (b) biodegradability that matches tissue growth; (c) highly interconnected macropores (100?s of microns) to promote ingrowth of cells, vascularization and nutrient delivery; (d) superimposed nanoporosity to guide cell attachment, migration and differentiation; and (e) bioactivity to catalyze the regeneration process. No synthetic product in the market satisfies all these requirements, including bioactive glass (BG) - the only manmade osteo-stimulating material for hard tissue regeneration. This I-Corps team has developed technology for fabricating a new class of bioactive material. The proposed technology provides excellent osteoinductivity and superior degradability compared to competing products, including those based on bioactive glass in the current market. It gives one the ability to tailor the degradation behavior of the scaffolds to specific patient types and nature of the defects without compromising the tissue growth. This I-Corps team has resolved the above challenges by introducing interconnected nanoporosity superimposed on macroporosity using novel fabrication methods: macroporosity to provide a basic substrate for tissue ingrowth, nanoporosity to enhance cell response and, the ability to tailor the scaffold?s degradation rate. The result is a novel fabrication technology portfolio for producing 'tailored amorphous multi-porous (TAMP)' scaffold that is matched to the needs of specific patient types. In vitro and in vivo tests have already demonstrated the proof-of-principle and potential for improved treatment of dental and orthopedic patients. The TAMP fabrication technology can be readily applied to new BG compositions with additional functionality such as antibacterial and anti-caries properties. When extended to fiber form, these TAMP structures are mechanically flexible. Thus, TAMP material technology is well poised for commercialization.